Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial

Summary Background Modified vaccinia virus Ankara (MVA) is a promising viral vector platform for the development of an H5N1 influenza vaccine. Preclinical assessment of MVA-based H5N1 vaccines showed their immunogenicity and safety in different animal models. We aimed to assess the safety and immuno...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases 2014-12, Vol.14 (12), p.1196-1207
Hauptverfasser: Kreijtz, Joost H C M, PhD, Goeijenbier, Marco, MD, Moesker, Fleur M, MD, van den Dries, Lennert, MD, Goeijenbier, Simone, BSc, De Gruyter, Heidi L M, BSc, Lehmann, Michael H, PhD, Mutsert, Gerrie de, BSc, van de Vijver, David A M C, PhD, Volz, Asisa, PhD, Fouchier, Ron A M, Prof, van Gorp, Eric C M, Prof, Rimmelzwaan, Guus F, Prof, Sutter, Gerd, Prof, Osterhaus, Albert D M E, Prof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!